RPTX — Repare Therapeutics Share News
0.000.00%
Last trade - 00:00- $112.94m
- $0.34m
- $53.48m
Brief: Repare Therapeutics Inc - Initial Tresr Data Provide Clinical Proof Of Concept, Validate Sniprx Platform For Molecular Selection Of Tumors For Therapy With Rp-3500
Brief: Repare Issues Statement On Inadvertent Issuance Of Abstract By ANE Conference
Brief: Repare Therapeutics Appoints Thomas Civik To Its Board And As New Chairman
Repare Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Repare Therapeutics Provides Business Update And Reports Second Quarter 2021 Financial Results
Repare Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Repare Therapeutics Files For Mixed Shelf Offering; Size Not Disclosed
Repare Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Repare Therapeutics Reports Q1 Loss Per Share $0.58
Brief: Repare Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Rp-6306, A First-In-Class, Selective, Oral Inhibitor Of Pkmyt1
Brief: Mpm Bioventures 2014 LP Reports 6.4% Stake In Repare Therapeutics
Brief: Repare Therapeutics Reports Q4 2020 Financial Results
Brief: Versant Ventures Files Early Warning Report In Respect Of Repare Therapeutics Inc
Brief: Repare Therapeutics Added To Nasdaq Biotechnology Index
Brief: Repare Therapeutics Reports Third Quarter 2020 Financial Results And Operational Highlights
Brief: Repare Therapeutics Reports Q2 Loss Per Share $2.45
Brief: Repare Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of Rp-3500
Brief: Versant Venture Capital VI L.P. Reports 9.3% Stake In Repare Therapeutics
Brief: BVF Partners LP Reports 5.3% Passive Stake In Repare Therapeutics Inc As Of June 19